RNS Number : 8908F MaxCyte, Inc. 10 November 2022 MaxCyte Reports Third Quarter 2022 Financial Results 22% Year-Over-Year Core Business Revenue Growth in Third Quarter 2022 Reiterates 2022 Revenue Guidance ROCKVILLE, MD , November 10, 2022 - MaxCyte, Inc.
ROCKVILLE, Md., Nov. 02, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support
RNS Number : 0728F MaxCyte, Inc. 02 November 2022 MaxCyte to Participate in Upcoming Investor Conferences ROCKVILLE, MD , November 2, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery,
RNS Number : 8870E MaxCyte, Inc. 01 November 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 1 November 2022 : MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to
RNS Number : 1498D MaxCyte, Inc. 17 October 2022 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development
RNS Number : 6329C MaxCyte, Inc. 12 October 2022 MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022 ROCKVILLE, MD , October 12, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform
RNS Number : 5404B MaxCyte, Inc. 03 October 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") TOTAL VOTING RIGHTS AND BLOCK LISTING RETURN Total Voting Rights Date: 3 October 2022 : MaxCyte ( Nasdaq: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on
Vertex Pharmaceuticals will continue to use MaxCyte’s Flow Electroporation ® technology and ExPERT ™ platform to support gene-edited cell therapy exa-cel, formerly known as CTX001™ for hemoglobinopathies ROCKVILLE, Md., Sept. 28, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a
